Literature DB >> 35530277

The interaction of p53 and DNA repair gene mutations and their impact on tumor mutation burden and immune response in human malignancies.

Xuemin Xue1, Lin Dong1, Edwina Burke2, Liyan Xue1, Yong-Jie Lu2.   

Abstract

P53 suppresses tumorigenesis through multiple cellular functions/mechanisms, including genomic stability surveillance. Recently, it has also be reported for its role in cancer immune response modulation. Deficiency in DNA repair pathways lead to the accumulation of genomic alterations and tumor mutation burden and in consequence resulting in the activation of immune response. We investigated the interaction of p53 and DNA repair gene mutations and their impact on tumor mutation burden and immune response in human malignancies by mining cBioPortal data of a range of human cancers. We found that in the majority of human cancers, p53 mutations are equally distributed between DNA repair gene mutation positive and negative cases and in a number of human cancers, p53 and DNA repair gene mutations have a tendency of co-occurrence. Only in colorectal cancer, there is a tendency of 'mutual exclusivity' of mutations in p53 and DNA repair genes. In most tumors, p53 and DNA repair gene mutations have synergistic/additive effect in increasing tumor mutation burden, but not in colorectal cancer where they are mutually exclusive. The impact of p53 and DNA repair gene mutations and their interaction on tumor microenvironment immune cells are complex and tumor type specific and not always correlated with tumor mutation burden. In colorectal cancers, these two types of mutations resulted in similar immune cell subpopulation changes and in tumors where the mutations have a tendency of co-occurrence, p53 showed dominant roles on immune response, although they can also counter-act each other for their effect on certain immune cell subtypes. AJCR
Copyright © 2022.

Entities:  

Keywords:  DNA repair gene; Gene mutation; P53; tumor infiltrating immune cell population; tumor mutation burden

Year:  2022        PMID: 35530277      PMCID: PMC9077057     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  22 in total

Review 1.  Immunotherapy and predictive immunologic profile: the tip of the iceberg.

Authors:  Tatiana Cunha Pereira; Paulo Rodrigues-Santos; Jani Sofia Almeida; Fábio Rêgo Salgueiro; Ana Raquel Monteiro; Filipa Macedo; Rita Félix Soares; Isabel Domingues; Paula Jacinto; Gabriela Sousa
Journal:  Med Oncol       Date:  2021-03-31       Impact factor: 3.064

2.  p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.

Authors:  Liz J Valente; Daniel H D Gray; Ewa M Michalak; Josefina Pinon-Hofbauer; Alex Egle; Clare L Scott; Ana Janic; Andreas Strasser
Journal:  Cell Rep       Date:  2013-05-09       Impact factor: 9.423

3.  Cancer type-dependent correlations between TP53 mutations and antitumor immunity.

Authors:  Lin Li; Mengyuan Li; Xiaosheng Wang
Journal:  DNA Repair (Amst)       Date:  2020-01-24

Review 4.  Human DNA repair genes, 2005.

Authors:  Richard D Wood; Michael Mitchell; Tomas Lindahl
Journal:  Mutat Res       Date:  2005-09-04       Impact factor: 2.433

5.  Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence.

Authors:  Tongyuan Li; Ning Kon; Le Jiang; Minjia Tan; Thomas Ludwig; Yingming Zhao; Richard Baer; Wei Gu
Journal:  Cell       Date:  2012-06-08       Impact factor: 41.582

6.  Human DNA repair genes.

Authors:  R D Wood; M Mitchell; J Sgouros; T Lindahl
Journal:  Science       Date:  2001-02-16       Impact factor: 47.728

Review 7.  Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches.

Authors:  Felix Dietlein; Lisa Thelen; H Christian Reinhardt
Journal:  Trends Genet       Date:  2014-07-10       Impact factor: 11.639

8.  Targeting a neoantigen derived from a common TP53 mutation.

Authors:  Emily Han-Chung Hsiue; Katharine M Wright; Jacqueline Douglass; Michael S Hwang; Brian J Mog; Alexander H Pearlman; Suman Paul; Sarah R DiNapoli; Maximilian F Konig; Qing Wang; Annika Schaefer; Michelle S Miller; Andrew D Skora; P Aitana Azurmendi; Michael B Murphy; Qiang Liu; Evangeline Watson; Yana Li; Drew M Pardoll; Chetan Bettegowda; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Sandra B Gabelli; Shibin Zhou
Journal:  Science       Date:  2021-03-01       Impact factor: 47.728

Review 9.  Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.

Authors:  Pengfei Zhao; Li Li; Xiaoyue Jiang; Qin Li
Journal:  J Hematol Oncol       Date:  2019-05-31       Impact factor: 17.388

Review 10.  Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.

Authors:  Dongkui Song; Thomas Powles; Lei Shi; Lirong Zhang; Molly A Ingersoll; Yong-Jie Lu
Journal:  J Pathol       Date:  2019-06-24       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.